SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as investors react to a significant earnings miss and negative free cash flow caused by massive capital expenditure, sparking intense debate between those betting on long-term AI and robotics growth and those criticizing the company's valuation and automotive margins. The conversation is further fueled by market-wide volatility and speculative talk regarding a potential merger with SpaceX, leaving the community divided between aggressive dip-buying and warnings of further downside.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is facing significant market volatility as investors weigh strong cloud segment growth and revenue beats against concerns over aggressive capital expenditure increases and rising AI infrastructure costs. The community remains deeply divided, with some investors viewing the dip as a prime long-term buying opportunity in a dominant AI leader, while others express caution regarding near-term margin pressures and the long-term ROI of heavy AI spending.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The S&P 500 is facing volatility as investors weigh disappointing earnings from mega-cap tech giants against escalating geopolitical tensions in the Middle East, including rising oil prices. Community members are actively debating the potential for a market breakdown, with significant focus on the impact of surging bond yields and the sustainability of high AI capital expenditures.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing volatility as investors weigh a strong earnings beat and significant cloud growth against the company's aggressive and rising capital expenditure on AI infrastructure. The community is sharply divided, with bulls pointing to robust cloud demand and long-term AI potential, while bears are expressing concern over negative free cash flow and the sustainability of massive infrastructure spending.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as traders closely monitor high-stakes earnings reports from major tech companies, while weighing the impact of rising bond yields and geopolitical tensions on index stability. The community is actively debating whether these tech giants can justify their massive AI-related capital expenditures, creating a divide between those anticipating a major breakdown and others looking for dip-buying opportunities.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors weigh significant order growth in its AI and cloud sectors against broader market volatility ahead of upcoming earnings. While some community members remain skeptical of the stock's recent performance, bulls are highlighting the company's strategic pivot toward AI-native infrastructure as a key long-term catalyst.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX shares are experiencing intense downward pressure as investors grow increasingly anxious over massive upcoming share lock-up expirations, which threaten to flood the market with new supply. The broader community is deeply divided, with vocal bears highlighting the stock's lofty valuation and high cash burn, while bullish retail investors are closely monitoring the upcoming Starship launch as a potential catalyst for a short squeeze.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is capturing significant market attention following a $400 million sole-source defense contract for critical electrical steel and continued progress on potential strategic partnerships. The community remains deeply divided, with bulls pointing to strong HRC pricing and infrastructure-related catalysts while bears warn of debt levels, management performance, and historical volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently facing heightened volatility and bearish sentiment ahead of its upcoming earnings call, with the community intensely debating the company's timeline for commercial production and manufacturing scalability. While bulls point to recent partnerships like Honda as validation of the technology's long-term potential, bears are increasingly focused on the lack of revenue, insider selling, and the challenging path to mass-producing solid-state batteries.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending after reporting strong Q2 results that topped estimates and prompted raised full-year guidance, fueled by a record backlog and surging demand in Aeronautics and Missiles. The community is actively discussing the stock's connection to Ondas Holdings' Sanctum counter-UAS platform and debating whether the current defense spending cycle warrants a sustained long-term uptrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SLS the entire purpose of bear posts like this is to scare new investors into selling. Those of us have been here for a long time tend to ignore these posts and are completely un persuaded. The purpose of this response is for the benefit of the new investors who are the targets of this nonsense.

First of all with a username like Seedy do we really need to say more? Seedy is pretty much exactly what the content is of this user’s substance.

Seedy’s “high probability of failure” thesis is a house of cards built on a foundations of quicksand - a sea of assumptions being presented as facts.  They are no such thing.

First, Seedy is assuming the BAT arm of Regal is dramatically outperforming because the trial has taken longer than expected.  Nonsense.

Regal is still blinded. Nobody outside the IMDC knows whether the longer survival is coming from GPS, BAT, or both. Saying “the control WILL outperform” isn’t analysi - it’s speculation.  ￼ Moreover the historical studies of how BAT performs ￼ and maintaining remission or not on CD side, they cut the other way and demonstrate that these drugs do not maintain remission for long periods of time, especially at the CR2 stage.   Indeed, when the leading BAT drugs in Regal, Ven/Aza were put through a phase 3 clinical trial for AML remission maintenance, the manufacturer HALTED the trial midstream - citing low enrollment.  

Surely, $ABBV a major pharmaceutical company with every financial incentive for this trial to finish if it were to be successful and put these drugs on the market for CR two maintenance could’ve and would’ve solved this problem if it thought the trial would be successful.  

Second, Seedy completely ignores the evidence that supports GPS while highlighting only the negatives. 

The Phase 2 AML CR2 study for GPS showed survival that was several times longer than historical controls and is the entire reason Regal exists. Does that guarantee success? Of course not. But pretending it never happened isn’t an honest review of the data.  It is nothing but bear FUD.

Seedy also treats every prior GPS study as a “failure,” which simply isn’t true. Several studies demonstrated strong WT1 immune responses and encouraging survival signals but were small, early-stage trials that weren’t designed to prove efficacy. There’s a huge difference between “not statistically definitive” and “the mechanism doesn’t work.”

Seedy also ignores the growing body of evidence that WT1 vaccines can generate meaningful anti-leukemia immune responses. The recent pediatric WT1 vaccine study produced excellent long-term survival and showed that patients who mounted an immune response lived dramatically longer. Different study? Yes. Different vaccine? Yes. But it directly contradicts the claim that WT1 vaccines are biologically incapable of working.

Seedy’s statistical argument is misleading too. He’s acting as if Regal was designed with “no cushion.” That’s not how clinical trials work. The 0.636 hazard ratio in Regal which defines success is simply the statistical hurdle needed to declare success—not a prediction of where GPS will actually land.

Finally, if the bear case is so obvious, why has Regal’s independent Data Monitoring Committee repeatedly allowed the trial to continue? They have seen the unblinded data. They stopped neither for futility nor for safety concerns. That doesn’t mean Regal will succeed—but it certainly doesn’t support the claim that failure is virtually inevitable.

In short, Seedy tortures the evidence and does gyrations to back into his conclusion that Regal will fail.   His calling failure a “high probability” while ignoring the strongest supporting data, dismissing positive studies, and presenting speculation as fact isn’t objective analysis—it’s cherry-picking.

There are no guarantees in any phase 3 clinical trial. Regal included. But at least to me, Seedy has presented nothing making me believe that Regal is going to fail.  To me the evidence points strongly the other way.  

To me there is no super BAT and the incredibly long survival of approximately 40% of the Regal patients a minimum of 28 months to move four years cannot be explained by BAT.

Finally, are Pharma Bro and “Seedy” the same person?  I don’t know that, of course. But it certainly wouldn’t shock me.  Once a convicted securities fraudster with a LIFETIME BAN from the pharmaceutical industry always a securities fraudster. 

Of course, this is not financial advice and do your own due diligence.

NONE

Wei Bull

Paul

Salty Fish

Ludo

Evan Webb

Rick Glowaki

Polsky007

Andy

Lee R Mason

Captain

Bob Zoo

$SLS https://x.com/i/status/2079941669135188300

this is the post which Martin Shkreli commented. I&#39;m no expert in this field, so I&#39;m asking you: doesn&#39;t this analysis sound extremely weak and superficial?
At this point most of the short&#39;s DDs seem gibberish, I can&#39;t find any solid point.
But, again, I want to hear your fact-checking.

Thank you!

sls shortConclusion: high probability of failureI've kept it short because sometimes it really is just that straightforward. $sls in a memesque frenzy, has traded very irrationally due to its short interest most of this year. Folk piling in trying to cause a short squeeze...

Seedy19 on X (formerly Twitter): "$sls shortConclusion: high probability of failureI've kept it short because sometimes it really is just that straightforward. $sls in a memesque frenzy, has traded very irrationally due to its short interest most of th...

StockTwits For Android 

SELLAS Life Sciences Group Inc

Kelly Mone

StockTwits for iOS

Abbvie Inc

 the entire purpose of bear posts like this is to scare new investors into selling. Those of us have been here for a long time tend to ignore these posts and are completely un persuaded. The purpose of this response is for the benefit of the new investors who are the targets of this nonsense.

First of all with a username like Seedy do we really need to say more? Seedy is pretty much exactly what the content is of this user’s substance.

Seedy’s “high probability of failure” thesis is a house of cards built on a foundations of quicksand - a sea of assumptions being presented as facts.  They are no such thing.

First, Seedy is assuming the BAT arm of Regal is dramatically outperforming because the trial has taken longer than expected.  Nonsense.

Regal is still blinded. Nobody outside the IMDC knows whether the longer survival is coming from GPS, BAT, or both. Saying “the control WILL outperform” isn’t analysi - it’s speculation.  ￼ Moreover the historical studies of how BAT performs ￼ and maintaining remission or not on CD side, they cut the other way and demonstrate that these drugs do not maintain remission for long periods of time, especially at the CR2 stage.   Indeed, when the leading BAT drugs in Regal, Ven/Aza were put through a phase 3 clinical trial for AML remission maintenance, the manufacturer HALTED the trial midstream - citing low enrollment.  

Surely, 

 a major pharmaceutical company with every financial incentive for this trial to finish if it were to be successful and put these drugs on the market for CR two maintenance could’ve and would’ve solved this problem if it thought the trial would be successful.  

Second, Seedy completely ignores the evidence that supports GPS while highlighting only the negatives. 

The Phase 2 AML CR2 study for GPS showed survival that was several times longer than historical controls and is the entire reason Regal exists. Does that guarantee success? Of course not. But pretending it never happened isn’t an honest review of the data.  It is nothing but bear FUD.

Seedy also treats every prior GPS study as a “failure,” which simply isn’t true. Several studies demonstrated strong WT1 immune responses and encouraging survival signals but were small, early-stage trials that weren’t designed to prove efficacy. There’s a huge difference between “not statistically definitive” and “the mechanism doesn’t work.”

Seedy also ignores the growing body of evidence that WT1 vaccines can generate meaningful anti-leukemia immune responses. The recent pediatric WT1 vaccine study produced excellent long-term survival and showed that patients who mounted an immune response lived dramatically longer. Different study? Yes. Different vaccine? Yes. But it directly contradicts the claim that WT1 vaccines are biologically incapable of working.

Seedy’s statistical argument is misleading too. He’s acting as if Regal was designed with “no cushion.” That’s not how clinical trials work. The 0.636 hazard ratio in Regal which defines success is simply the statistical hurdle needed to declare success—not a prediction of where GPS will actually land.

Finally, if the bear case is so obvious, why has Regal’s independent Data Monitoring Committee repeatedly allowed the trial to continue? They have seen the unblinded data. They stopped neither for futility nor for safety concerns. That doesn’t mean Regal will succeed—but it certainly doesn’t support the claim that failure is virtually inevitable.

In short, Seedy tortures the evidence and does gyrations to back into his conclusion that Regal will fail.   His calling failure a “high probability” while ignoring the strongest supporting data, dismissing positive studies, and presenting speculation as fact isn’t objective analysis—it’s cherry-picking.

There are no guarantees in any phase 3 clinical trial. Regal included. But at least to me, Seedy has presented nothing making me believe that Regal is going to fail.  To me the evidence points strongly the other way.  

To me there is no super BAT and the incredibly long survival of approximately 40% of the Regal patients a minimum of 28 months to move four years cannot be explained by BAT.

Finally, are Pharma Bro and “Seedy” the same person?  I don’t know that, of course. But it certainly wouldn’t shock me.  Once a convicted securities fraudster with a LIFETIME BAN from the pharmaceutical industry always a securities fraudster. 

Of course, this is not financial advice and do your own due diligence.